30/11/2018
Marie Skłodowska-Curie Actions

I-Direct: "10 PhD positions in breakthrough research on the rapidly expanding and high impact field of cancer immunotherapy and nanotech drug formulation"


  • ORGANISATION/COMPANY
    University Medical Center Groningen (UMCG)
  • RESEARCH FIELD
    Biological sciencesOther
    ChemistryOther
  • RESEARCHER PROFILE
    First Stage Researcher (R1)
  • APPLICATION DEADLINE
    28/02/2019 00:00 - Europe/Brussels
  • LOCATION
    Multiple locations, see work locations below.
  • TYPE OF CONTRACT
    Temporary
  • JOB STATUS
    Full-time
  • HOURS PER WEEK
    40
  • OFFER STARTING DATE
    01/03/2019
  • EU RESEARCH FRAMEWORK PROGRAMME
    H2020 / Marie Skłodowska-Curie Actions
  • REFERENCE NUMBER
    H2020-MSCA-ITN-I-Direct
  • MARIE CURIE GRANT AGREEMENT NUMBER
    813871

I-Direct is a Marie Curie European Industrial Doctorate (EID) training network funded by the European Commission within the Horizon 2020 research and innovation action. The I-Direct programme aims to develop innovative academic and industrial antibody-based concepts and exploit state-of-the-art industrial design of nanotech-based drug formulation to develop the next-generation of cancer immunotherapeutics. The I-Direct network comprises 2 academic research institutions/universities and 3 companies and provides inter-sectoral training for a set of 10 early stage researchers, which will qualify them for a career in academia and/or industry. I-Direct activities will start on January 1, 2019. I-Direct partners located in the Netherlands, Germany, Czech Republic and Israel are recruiting 10 highly motivated PhD candidates interested in carrying out breakthrough research on the rapidly expanding and high impact field of cancer immunotherapy. Each ESR will crucially gain intersectoral experience in an individual ESR research project, with the main working period (36 months) of the ESR equally split into an academic and an industrial part of 18 months in different countries.

The 10 ESR research projects within the I-DireCT training network work in integrated and interconnected research program focused on therapeutically modifying the tumour micro-environment and (re)activation of anti-cancer immunity and corresponding Drug Delivery Systems (DDS). Specifically, we aim on the one hand to develop new tumour-targeted drugs to selectively block key innate and adaptive immune checkpoints, such as PD-1, TIM-3 and CD47, in the tumour micro-environment. Further, we aim to develop new tumour-targeted drugs to selectively activate key co-stimulatory receptors of the TNFRSF in the tumour micro-environment.

On the other hand suitable DDS systems will be developed for these drugs using modern drug formulations based on nanotechnology and surface chemistry to achieve tumor-localized release and optimal localized co-stimulation of anti-cancer immunity. The development will be attended by label free detection of protein interactions by means of advanced bioanalysis methods. Herewith, we aim to ensure induction and execution of anticancer immune responses in the absence of systemic immune-related side-effects.

Job Description:

The I-Direct research program focuses on offering a cutting-edge multidisciplinary training programme that will enable outstanding young scientists to generate breakthrough ideas and assume leading positions in academia and industry. This training programme includes an array of disciplines, ranging from biomedical sciences (e.g. immunology, antibody engineering) and physical sciences (e.g. chemistry, material science) to drug design & development. The 10 students will start between Jan 2019 and Jan 2020. Each position will be appointed for 36 months and dedicated to the following projects/partner labs:

  1. University Medical Center Groningen (UMCG), established in HANZEPLEIN 1, GRONINGEN 9713 GZ, Netherlands
  2. UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT (UKW), established in JOSEF-SCHNEIDERSTRASSE 2, WURZBURG 97080, Germany
  3. INOCURE SRO (INCU), established in KLIMENTSKA 1652/36, PRAHA 11000, Czech Republic
  4. Surflay Nanotec GmbH (SURF), established in MAX PLANCK STRASSE 3, BERLIN 12489, Germany
  5. KAHR MEDICAL LTD (KM), established in 1 KIRYAT HADASSAH, JBP BLDG, JERUSALEM 9109701, Israel

I-Direct students will gain substantial interdisciplinary and intersectoral experience with secondments in other labs of the network, including an equal time spent into an academic and an industrial research institute of 18 months in different countries, and will benefit from innovative training workshops and summer schools covering all PhD training aspects: Scientific education, Project Management, Communication skills, Career Development, etc.

 

Please apply for each ESR project separately. Please send your E-mail directly to the contact given in each of the 10 job offer. Please find the links to the job offers below.

 

ESR POSITIONS AND WORK LOCATION(s):

10 position(s) available at various locations (2 locations for each ESR, 18 months each)

ESR1: Development and preclinical validation of tumour-selective PD-1/PD-L1 immunotherapeutics and drug delivery systems

Netherlands/Czech Republic

ESR2: Cancer immunomodulation upon tumour-selective targeting of innate immune checkpoints

Netherlands/Germany

ESR3: Development, label free bioanalysis and preclinical validation of Adenosine-2A-Receptor (A2AR)-targeting bispecific antibodies

Germany/Netherlands

ESR4: Development of stimuli-sensitive particles for tumour-selective targeting of TIM-3/Galectin-9

Germany/Netherlands

ESR5: Targeted inhibition of novel immune checkpoints

Netherlands/Germany

ESR6: Development and characterization of antibody fusion proteins with tumour-restricted FcgR-independent co-stimulatory activity by targeting CD70

Germany/Czech Republic

ESR7: Development and characterization of antibody fusion proteins with tumour-restricted FcgR-independent co-stimulatory activity by targeting PD-L1

Germany/Czech Republic

ESR8: Development of stimuli-sensitive nanoparticles and in vivo evaluation of immune-stimulatory TNFSF ligand fusion proteins with FAP-restricted activity

Czech Republic/Germany

ESR9: Development of immunomodulatory Dual Signalling Proteins (DSPs) for cancer immunotherapy

Israel/The Netherlands

ESR10: Nanoparticles for targeted delivery to tumours

Czech Republic/The Netherlands

Eligibility criteria

As a mobile and early-stage researcher you have to fulfill the following conditions:

Definition of an early-stage researcher:

An early stage researcher (ESR) is defined as a student being in the first four years of his/her research career at the time of the recruitment and a student who does not have a doctoral degree. The research career starts after the degree that enables a student to proceed with a PhD (usually, the Master degree).

Mobility Rule:

At the time of the recruitment by the host laboratory, young researchers must not have resided or carried out their main activity (work, studies, etc.) in the country of their host laboratory for more than 12 months in the 3 years immediately before the recruitment date.

Background: Antibody technology, Label free bioanalysis SPR, QCM or similar; Nanoparticle synthesis; Biofunctionalization; Surface Chemistry;

Additional comments

Please check the individual job offers on the website https://i-direct-itn.eu/research/phd-projects.

 

Web site for additional job details

Required Research Experiences

  • RESEARCH FIELD
    Biological sciencesOther
  • YEARS OF RESEARCH EXPERIENCE
    1 - 4
  • RESEARCH FIELD
    ChemistryBiochemistry
  • YEARS OF RESEARCH EXPERIENCE
    1 - 4

Offer Requirements

  • REQUIRED LANGUAGES
    ENGLISH: Excellent

Skills/Qualifications

RESEARCH FIELD:

Biological/ Chemical sciences

YEARS OF RESEARCH EXPERIENCE:

1 - 4 years

REQUIRED EDUCATION LEVEL:

Biological/ Chemical sciences: Master Degree or equivalent

REQUIRED LANGUAGES:

ENGLISH: Excellent

 

Specific Requirements

As a mobile and early-stage researcher you have to fulfill the following conditions:

Definition of an early-stage researcher:

An early stage researcher (ESR) is defined as a student being in the first four years of his/her research career at the time of the recruitment and a student who does not have a doctoral degree. The research career starts after the degree that enables a student to proceed with a PhD (usually, the Master degree).

Mobility Rule:

At the time of the recruitment by the host laboratory, young researchers must not have resided or carried out their main activity (work, studies, etc.) in the country of their host laboratory for more than 12 months in the 3 years immediately before the recruitment date.

Background: Antibody technology, Label free bioanalysis SPR, QCM or similar; Nanoparticle synthesis; Biofunctionalization; Surface Chemistry

Map Information

Work location(s)
7 position(s) available at
UMCG
Netherlands
GRONINGEN
GRONINGEN
9713 GZ
HANZEPLEIN 1
5 position(s) available at
INOCURE SRO
Czech Republic
Praha
11000
KLIMENTSKA 1652/36
3 position(s) available at
UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Germany
Bayern
Würzburg
97080
JOSEF-SCHNEIDER-STRASSE 2
4 position(s) available at
Surflay Nanotec GmbH
Germany
Berlin
Berlin
12489
MAX PLANCK STRASSE 3
1 position(s) available at
Kahr Medical Ltd.
Israel
Jerusalem
9109701
1 Kiryat Hadassah

EURAXESS offer ID: 359742